Cao Xiu-Feng, Lü Jin, Zhu Bin, An Hong-Yin, Wang Shan, Wu Bi-Chao, Ji Lü, Tao Lei, Wang Dong-Dong
Department of Surgery, Oncology Center of Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing 210006, China.
Zhonghua Zhong Liu Za Zhi. 2010 Jun;32(6):452-5.
To investigate the role of postoperative chemoradiotherapy (CRT) as a multimodality treatment option for locally advanced thoracic esophageal squamous cell carcinoma (ESCC) by a prospective comparison between surgery alone and postoperative CRT.
Using preoperative computed tomography (CT)-based staging criteria, 158 patients with ESCC (stage II-III) were enrolled in this prospective study. With informed consent, the patients were randomized into two groups: postoperative CRT (78 cases) and surgery alone (S, 80 cases). After a few minor adjustments to the enrolled patients, the actual patients of postoperative CRT group and S group were 74 cases and 77 cases, respectively. Comparison of the complications, local recurrence rate, distant metastasis rate, survival rate and progression-free survival in the two groups was carried out.
With a median follow-up of 37.5 months, the 1-, 3-, 5-, 10-year overall survival (OS) rates were 91.0%, 62.8%, 42.3%, 24.4% and 87.5%, 51.3%, 33.8%, 12.5% for the postoperative CRT and S arm, respectively. A significant difference in OS was detected between the two arms (P = 0.0276). There was a significant difference of progression-free survival (PFS) between the two arms (P = 0.0136). The local recurrence rates in the postoperative CRT group and S group were 14.9% and 36.4%, respectively (P < 0.05). No significant difference was detected between the complications of the two groups (P > 0.05). Toxicities of chemoradiotherapy in the postoperative CRT arm were moderate, which can be relieved rapidly by adequate therapy.
Rational application of postoperative chemoradiotherapy can provide a benefit in progression-free survival and overall survival in patients with locally advanced esophageal squamous cell carcinoma.
通过对单纯手术与术后放化疗进行前瞻性比较,探讨术后放化疗(CRT)作为局部晚期胸段食管鳞状细胞癌(ESCC)多模式治疗方案的作用。
采用基于术前计算机断层扫描(CT)的分期标准,158例ESCC患者(II - III期)纳入本前瞻性研究。经患者知情同意,将患者随机分为两组:术后CRT组(78例)和单纯手术组(S组,80例)。对纳入患者进行一些微调后,术后CRT组和S组的实际患者分别为74例和77例。比较两组的并发症、局部复发率、远处转移率、生存率和无进展生存期。
中位随访37.5个月,术后CRT组和S组的1年、3年、5年、10年总生存率(OS)分别为91.0%、62.8%、42.3%、24.4%和87.5%、51.3%、33.8%、12.5%。两组间OS存在显著差异(P = 0.0276)。两组间无进展生存期(PFS)存在显著差异(P = 0.0136)。术后CRT组和S组的局部复发率分别为14.9%和36.4%(P < 0.05)。两组并发症之间未检测到显著差异(P > 0.05)。术后CRT组放化疗的毒性为中度,通过适当治疗可迅速缓解。
合理应用术后放化疗可使局部晚期食管鳞状细胞癌患者的无进展生存期和总生存期受益。